Lv52
1320 积分 2023-05-02 加入
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
9天前
已完结
Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer
10天前
已完结
Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses
12天前
已完结
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
12天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
17天前
已完结
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
18天前
已完结
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
18天前
已完结
Immunogenic Cell Death in Cancer Therapy
22天前
已完结
Immunogenic cell stress and death
22天前
已完结
Immune-Related Adverse Events and Efficacy—The More It Hurts, the Better It Works?
23天前
已完结
皖公网安备34019202002308
